Le Lézard
Classified in: Health
Subjects: TDS, MAT

Chemistree to Unveil VR Tour of Sugarleaf Facility at Lift - Vancouver


VANCOUVER, Jan. 10, 2020 /CNW/ - Chemistree Technology Inc. (CSE: CHM and CHM.wt) (US OTCQB: CHMJF) (the "Company" or "Chemistree"), announces that in conjunction with the January 10 and 11, 2020, Lift & Co Cannabis Expo in Vancouver Canada, Chemistree will unveil for our shareholders and potential new investors - a bold and exciting new virtual reality tour of our state-of-the-art Washington facility, to illustrate first hand what we do, and how we do it.

Chemistree Technology Inc. (CNW Group/Chemistree Technology Inc.)

Sugarleaf and its strategic partner, Chemistree, are pioneers in the cannabis trade, and owe their success to their commitment to innovation by spearheading bold new cultivation techniques that have rapidly made them the new industry standard. 

There is a myth within the industry that all a business needs to do is simply grow their product and bring it to market. Naturally, like most over simplified things, this couldn't be more untrue. Roughly half of licenced growers see little if any return on their investment because our industry demands rapid innovation and investment in order to reach its full potential. 

We also have to run a business that yields the highest possible returns for investors, and for a company to attract serious investors who truly understand the potential of the growing cannabis industry, we have to create exciting, new and innovative ways to explain to potential investors exactly what we do, why we do it, and how it works. Afterall, you can read truckloads of information and watch hours of YouTube videos and really only get a small sense of how one of our facilities really functions. 

Our team partnered with the great people at Growing Exposed, and this weekend we are rolling out our exciting new full virtual reality tour of the Sugarleaf facility. You will be able to completely pull back the curtain and experience a brand-new VR tour of Sugarleaf and see first hand exactly how we are setting new industry standards. 

Jeremy Deichen, Chemistree's Director of Marketing commented "when cannabis became legal for recreational use, many people believed it was going to be like the Wild West. In some respects, they were right, except it turned out that it is more like Silicon Valley than a broken-down old desert mine.  For that reason, our team will always seek the latest technology so that we can offer our customers the very best product possible, and our investors a brand new opportunity that will only mature and grow as we continue to learn and push technology forward."

The entire tour was filmed using Method Seven filters on a Go Max 360 Camera and captures every essence of our grow room in ways on VR can provide. 

This latest innovation was developed so that we can offer our potential investors the opportunity to step inside our facility for themselves, without a sales pitch, and see the full potential of their investment, but also so we can demonstrate our commitment to innovation at every level of our business from vendors to cultivation to marketing and every link in the chain. 

For more information, visit www.chemistree.ca.

Advisory
The Company wishes to inform shareholders that there are significant legal restrictions and regulations that govern the cannabis industry in both Canada and the United States.

Cannabis-related Practices or Activities are Illegal Under U.S. Federal Laws
The concepts of "medical cannabis" and "recreational cannabis" do not exist under U.S. federal law. The Federal Controlled Substances Act classifies "marihuana" as a Schedule I drug. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. As such, cannabis related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. Strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under U.S. federal law, nor will it provide a defence to any federal proceeding which may be brought against the Company. Enforcement of U.S. federal laws will be a significant risk to the business of the Company and any such proceedings brought against the Company may adversely affect the Company's operations and financial performance.

Further information regarding the legal status of cannabis related activities and associated risk factors, including, but not limited to, risk of enforcement actions, risks that third-party service providers, such as banking or financial institutions cease providing services to the Company, and the risk that Company may not be able to distribute profits, if any, from U.S. operations up to the Company, are included in the Prospectus, the Company's annual information form and other documents incorporated by reference therein and in the Company's Form 2A listing statement filed with the CSE and available under the Company's profile on SEDAR at www.sedar.com.

"Karl Kottmeier"         
President 

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Information set forth in this news release includes forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", "budget", "scheduled" and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation, statements about adding clients, building on the Company's initial product offerings, entry into of definitive agreements.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the Company's reports and filings with the applicable Canadian securities regulators. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made, and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

SOURCE Chemistree Technology Inc.


These press releases may also interest you

at 08:10
FirstWave Bio, Inc., a clinical-stage biotechnology company developing novel gut-targeted small molecules for inflammatory bowel disease and other serious conditions, today announced plans to initiate a Phase 2a/2b study in patients with COVID-19,...

at 08:10
Sangamo Therapeutics, Inc. , a genomic medicine company, today announced the closing of its previously announced sale of stock to Biogen Inc. and that the global licensing collaboration agreement with Biogen for the development and commercialization...

at 08:05
Merck , known as MSD outside the United States and Canada, announced today a commitment to strengthen health systems affected by the COVID-19 pandemic. Through Merck for Mothers, the company's global initiative to help end preventable maternal...

at 08:05
A new startup, i2O Therapeutics, has launched to commercialize innovations developed at Harvard University that may one day enable patients and clinicians to give up syringes in favor of pills. Using ionic liquid technologies developed in the lab...

at 08:05
X4 Pharmaceuticals, Inc. , a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present and conduct one-on-one meetings during the...

at 08:05
i2O Therapeutics, an innovative biotech company developing a platform for oral delivery of traditionally injectable biological drugs, announced today it has raised a $4 million seed funding round led by Sanofi Ventures and JDRF T1D Fund. Founded by...



News published on 10 january 2020 at 09:00 and distributed by: